Somewhere around 10 percent of the U.S. population suffers from chronic insomnia, and around a third of those take drugs to help them sleep. Scientists from Merck & Co. Inc. have reported scientific data in support of their contention that a new type of insomnia drug can give sweet dreams without the side effects that dog the current crop of sleep-inducing agents.
WASHINGTON – At the American Association for Cancer Research's annual meeting this week, scientists showed off the fruits of their labor. But as always, given cancer research's dismal translational success rate, there were also discussions of how to improve that labor in the first place.
WASHINGTON– As far as cellular processes go, mitosis seems like a natural target for cancer drugs. "Its major business is cell growth," Genentech Inc.'s Peter Jackson told the audience at the annual meeting of the American Association for Cancer Research (AACR). It's got kinases – lots of kinases. And there is a "vast array" of traditional chemotherapies that hits some aspect of the cell cycle.
Several presentations at the American Association for Cancer Research's (AACR) Annual Meeting this week underscored the size of the epigenetic space. Targeting epigenetic alterations has gone far beyond histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, which are the two classes of epigenetic enzymes that have approved drugs targeting them.
If you’re looking for a plenary speaker, pick a Pulitzer Prize winner. That was one of the corollary lessons to be had from the talk of Columbia University’s Siddhartha Mukherjee at the American Association for Cancer Research’s Annual Meeting on Sunday, which was somewhat like a Cliff Notes version of his Pulitzer-Prize winning epic on cancer, “The Emperor of all Maladies.” Mukherjee regaled the audience with an apocryphal tale of a historian who was asked to predict the future of the Soviet Union and answered that “in the Soviet Union, the future is quite easy to predict. The problem is...
Close to 20,000 attendees from more than 60 countries are expected to converge on Washington for the American Association for Cancer Research's (AACR) annual meeting this weekend and early next week, for science, clinical advances and, the meeting's organizers hope, perhaps even some politics.
If current dreams of an AIDS-free generation are to be realized, it will be necessary to develop an effective vaccine against HIV. And such a vaccine will need to induce a broadly neutralizing antibody.
Teams led by scientists from the Scripps Research Institute and the Seattle Biomedical Research Institute reported last week that they have engineered and identified, respectively, parts of HIV that can strongly stimulate naïve B cells to produce the sorts of antibodies that can ultimately become broadly effective against HIV – a step toward the development of an HIV vaccine that has long eluded researchers.
By using a single-cell proteomics approach, researchers have discovered that the mammalian target of rapamycin, or mTOR protein, may be hardest to drug at oxygen levels that are often found in tumors.
Scientists have discovered that normal brain activity induces DNA damage, and that such damage is induced more strongly, and repaired more slowly, in the brains of mice with Alzheimer's disease. The findings suggest new possibilities for fighting neuronal damage in Alzheimer's disease, and such DNA breaks may also be a newly discovered mechanism of memory storage under normal circumstances.
